OBJECTIVE: To compare the clinical and laboratory findings between adjuvant therapy performed and not performed on peritoneal cytology-positive patients with cytology-negative cases of surgical-pathologic Stage I endometrial cancer. METHODS:Twelve peritoneal cytology-positive and 12 negative surgical-pathologic StageI endometrial cancer cases were used in the study. Adjuvant radiotherapy was performed for six cytology-positive patients (group I); no adjuvant therapy was performed for six cytology-positive (group II) and 12 cytology-negative patients (control group). Pelvic examination, vaginal cytology, serum CA125 levels and routine blood tests were checked at two-month intervals for two years and at six-month intervals for the third year. Abdominopelvic computerized tomography was planned annually. RESULTS: There was no statistically significant difference among the three groups and no recurrence in any group. CONCLUSION: We do not recommend adjuvant therapy for cytology-positive patients if the tumor is confined to the uterus.
RCT Entities:
OBJECTIVE: To compare the clinical and laboratory findings between adjuvant therapy performed and not performed on peritoneal cytology-positive patients with cytology-negative cases of surgical-pathologic Stage I endometrial cancer. METHODS: Twelve peritoneal cytology-positive and 12 negative surgical-pathologic Stage I endometrial cancer cases were used in the study. Adjuvant radiotherapy was performed for six cytology-positive patients (group I); no adjuvant therapy was performed for six cytology-positive (group II) and 12 cytology-negative patients (control group). Pelvic examination, vaginal cytology, serum CA125 levels and routine blood tests were checked at two-month intervals for two years and at six-month intervals for the third year. Abdominopelvic computerized tomography was planned annually. RESULTS: There was no statistically significant difference among the three groups and no recurrence in any group. CONCLUSION: We do not recommend adjuvant therapy for cytology-positive patients if the tumor is confined to the uterus.
Authors: Melissa A Geller; Joseph J Ivy; Rahel Ghebre; Levi S Downs; Patricia L Judson; Linda F Carson; Amy L Jonson; Kathryn Dusenbery; Rachel Isaksson Vogel; Matthew P Boente; Peter A Argenta Journal: Gynecol Oncol Date: 2011-01-15 Impact factor: 5.482
Authors: Howard D Homesley; Virginia Filiaci; Susan K Gibbons; Harry J Long; David Cella; Nick M Spirtos; Robert T Morris; Koen DeGeest; Roger Lee; Anthony Montag Journal: Gynecol Oncol Date: 2008-12-23 Impact factor: 5.482